GSK to Acquire RAPT Therapeutics for ~$2.2B

Shots: GSK has entered into a definitive agreement to acquire RAPT Therapeutics, incl. its P-II asset ozureprubart with data expected in 2027, strengthening GSK’s inflammatory & immunology pipeline As per the deal, GSK will acquire RAPT for $58/share, representing the aggregate equity value of $2.2B & an estimated upfront investment of $1.9B cash; closing expected…

ByRidhi RastogiJanuary 20, 2026

RAPT Therapeutics Receives the US FDA’s IND Clearance to Evaluate RPT904 for Food Allergy

Shots: The US FDA has granted IND clearance to initiate P-IIb (prestIgE) trial of RPT904 for the treatment of pts with IgE-mediated food allergy by the end of 2025 The P-IIb (prestIgE) trial will assess RPT904 (SC; loading at Wk. 2, then Q8W or Q12W) vs PBO in 2 parts: In Part 1, ~100 pts with ≥1 food…

ByRidhi RastogiSeptember 30, 2025

Know Your Investor: Deep Track Capital (June’25 Edition)

Shots:    Welcome to the 2025 edition of Know Your Investor, highlighting top venture capital firms driving healthcare innovation This edition features Deep Track Capital, a firm dedicated to investing in life sciences companies that are advancing innovations to improve public health In 2024, Deep Track Capital invested approximately $4.35B across six funding rounds, adding 32…

ByPrince GiriJune 5, 2025

GSK to Acquire RAPT Therapeutics for ~$2.2B

RAPT Therapeutics Receives the US FDA’s IND Clearance to Evaluate RPT904 for Food Allergy

Know Your Investor: Deep Track Capital (June’25 Edition)

Contact US

FOLLOW US